The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
The amplicon sequencing method, called resistance mutation sequencing (RM-seq), may help in detecting resistance earlier than traditional techniques.
NYSDOH's move away from susceptibility testing for isolates that are known to be pan-susceptible will be coordinated with similar international efforts.
Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.
Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The new plant will serve as the company's hub for launching multiplexed molecular diagnostic kits for tuberculosis and other infectious disease.
The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.
TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.
In PLOS this week: mutation linked to progressive ataxia in Charolais cattle, microRNA expression levels linked to colorectal cancer, and more.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.